Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Molecular MRD Monitoring Is Feasible in the Majority of Children with AML and Is Highly Predictive of Outcome: Results from the International MyeChild01 Study

Blood (2019) 134 (Supplement_1): 1393.

https://doi.org/10.1182/blood-2019-125257

Published: 2019

Journal Articles

Quantitative Analysis of MLL Fusion Transcripts By Droplet Digital PCR to Monitor Minimal Residual Disease in MLL -Rearranged Acute Myeloid Leukemia

Sadia Afrin, PhD, Christine RC Zhang, PhD, Claus Meyer, PhD, Mellissa Maybury, PhD, Thy Pham, BAppSc (Hons), Nicola Venn, BSc, Toby N Trahair, MBBS FRACP PhD, Rosemary Sutton, PhD, Rolf Marschalek, PhD, Lynn Fink, PhD, Andrew S. Moore, MBBS, FRACP, PhD

Blood (2018) 132 (Supplement 1): 2746.

https://doi.org/10.1182/blood-2018-99-117761

Published: 2018

Journal Articles

Aberrant Splicing of KMT2A As a Potential Molecular MRD Marker in Cytogenetically-Normal AML

Christine RC Zhang, PhD, Sadia Afrin, PhD, Mellissa Maybury, PhD, Thy Pham, BAppSc (Hons), Lynn Fink, PhD, Andrew S. Moore, MBBS, FRACP, PhD

Blood (2018) 132 (Supplement 1): 1504.

https://doi.org/10.1182/blood-2018-99-117759

Published: 2018

Journal Articles

Identification of Multiple, Patient-Specific MLL Fusion Transcript Isoforms in Childhood Leukemia Using Anchored Multiplex PCR-Based Enrichment (AMP-E)

Sadia Afrin, BSc (Hons) MSc, Claus Meyer, PhD, Caedyn L. Stinson, BSc, Thy Pham, BAppSc (Hons), Timothy J.C. Bruxner, PhD, Nicola C. Venn, BSc (Hons), Toby N. Trahair, MBBS FRACP PhD, Rosemary Sutton, BSc PhD, Rolf Marschalek, PhD, Lynn Fink, PhD, Andrew S. Moore, MBBS FRACP PhD

Blood (2016) 128 (22): 2908.

https://doi.org/10.1182/blood.V128.22.2908.2908

Published: 2016

Journal Articles

Genomic Landscape of Pediatric Mixed Phenotype Acute Leukemia

Thomas B. Alexander, MD MPH, Zhaohui Gu, PhD, John K Choi, MD, Mignon L. Loh, MD, John Horan, MD MPH, Barbara Buldini, MD, Giuseppe Basso, Sarah Elitzur, MD, C. Michel Zwaan, MD PhD, Valerie de Haas, MD PhD, Allen Eng Juh Yeoh, MD, Dirk Reinhardt, MD PhD, Daisuke Tomizawa, MD, PhD, Tim Lammens, Barbara De Moerloose, MD, Li Zhou, PhD, Hiroki Hori, MD PhD, Anthony V. Moorman, PhD, Andrew S. Moore, MBBS FRACP PhD, Ondrej Hrusak, MD PhD, Soheil Meshinchi, MD PhD, Etan Orgel, MD MS, Meenakshi Devidas, PhD, Stephen P. Hunger, MD, Jamie M Guidry Auvil, Malcolm A. Smith, MD PhD, Tanja M. Davidsen, PhD, Leandro C. Hermida, Patee Gesuwan, Marco A. Marra, PhD, Yussanne Ma, PhD, Andrew J. Mungall, Richard Moore, PhD, Daniela S. Gerhard, PhD, Xueyuan Cao, Lei Shi, PhD, Stanley Pounds, PhD, Hiroto Inaba, MD PhD, Charles Mullighan, MBBS, MSc, MD

Blood (2016) 128 (22): 454.

https://doi.org/10.1182/blood.V128.22.454.454

Published: 2016

Journal Articles

The Preclinical Efficacy of a Novel Telomerase Inhibitor, Imetelstat, in AML - a Randomized Trial in Patient-Derived Xenografts

Claudia Bruedigam, PhD, Brad Wackrow, Axia Song, Amy H Porter, Stanley Chun-Wei Lee, PhD, Andrew S. Moore, MBBS FRACP PhD, Omar Abdel-Wahab, MD, Steven W Lane, PhD

Blood (2016) 128 (22): 578.

https://doi.org/10.1182/blood.V128.22.578.578

Published: 2016

Journal Articles

Rare and Common Germline Variants Contribute to Occurrence of Myelodysplastic Syndrome

Blood (2015) 126 (23): 1644.

https://doi.org/10.1182/blood.V126.23.1644.1644

Published: 2015

Journal Articles

Inhibition of Telomerase with Imetelstat Is Detrimental to Leukemia Stem Cells in Acute Myeloid Leukemia (AML)

Claudia Bruedigam, Frederik Otzen Bagger, Florian H Heidel, MD, Catherine Kuhn, Solene Guignes, Axia Song, Rebecca Austin, Therese Vu, Erwin M Lee, PhD, Andrew S. Moore, MBBS, FRACP, PhD, Richard B. Lock, PhD, Lars Bullinger, MD PhD, Geoff R Hill, MD, Steven W Lane, MD PhD

Blood (2014) 124 (21): 2322.

https://doi.org/10.1182/blood.V124.21.2322.2322

Published: 2014

Journal Articles

The Survivin Suppressant YM155 (Sepantronium Bromide) Has Potent Pre-Clinical Activity Against Pediatric Acute Myeloid Leukemia

Erica B. Little, BSc, BCApSc, MSc, Amanda M. Smith, BBMSc (Hons), Andjelija Zivanovic, BPharm (Hons), MSc, Alfred K.S. Liu, BSc, Shannon Waldron, BAppSc, Wendy J. Ingram, BSc (Hons), PhD, Andrew R. Hallahan, MBBS, FRACP, Andrew S. Moore, MBBS, FRACP, PhD

Blood (2013) 122 (21): 3957.

https://doi.org/10.1182/blood.V122.21.3957.3957

Published: 2013

Journal Articles

The Ratio of Alternate BIRC5 (Survivin) Splice Variants Correlates with Refractory Disease and Poor Outcome in Children with Acute Myeloid Leukemia: A Report From the Children's Oncology Group,

Andrew S. Moore, MBBS, FRACP, Todd A. Alonzo, PhD, Robert B. Gerbing, M.A., Beverly Lange, MD, Nyla A. Heerema, PhD, Janet Franklin, MD, MPH, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, Alan S. Gamis, MD, MPH, Soheil Meshinchi, MD, Ph.D.

Blood (2011) 118 (21): 3555.

https://doi.org/10.1182/blood.V118.21.3555.3555

Published: 2011

Journal Articles

Resistance to Selective FLT3 Inhibitors, Driven by FLT3 Ligand and FLT3 Point Mutations, Can Be Overcome with the Dual FLT3-Aurora Kinase Inhibitor CCT241736,

Andrew S. Moore, MBBS, FRACP, Amir Faisal, Vassilios Bavetsias, David Gonzalez de Castro, PhD, Chongbo Sun, Butrus Atrash, Melanie Valenti, Alexis de Haven Brandon, Sian Avery, Andrew DJ Pearson, Paul Workman, Julian Blagg, Florence I Raynaud, Suzanne A Eccles, Spiros Linardopoulos

Blood (2011) 118 (21): 3492.

https://doi.org/10.1182/blood.V118.21.3492.3492

Published: 2011

NARROW

Molecular MRD Monitoring Is Feasible in the Majority of Children with AML and Is Highly Predictive of Outcome: Results from the International MyeChild01 Study

Quantitative Analysis of MLL Fusion Transcripts By Droplet Digital PCR to Monitor Minimal Residual Disease in MLL -Rearranged Acute Myeloid Leukemia

Aberrant Splicing of KMT2A As a Potential Molecular MRD Marker in Cytogenetically-Normal AML

Identification of Multiple, Patient-Specific MLL Fusion Transcript Isoforms in Childhood Leukemia Using Anchored Multiplex PCR-Based Enrichment (AMP-E)

Genomic Landscape of Pediatric Mixed Phenotype Acute Leukemia

The Preclinical Efficacy of a Novel Telomerase Inhibitor, Imetelstat, in AML - a Randomized Trial in Patient-Derived Xenografts

Rare and Common Germline Variants Contribute to Occurrence of Myelodysplastic Syndrome

Inhibition of Telomerase with Imetelstat Is Detrimental to Leukemia Stem Cells in Acute Myeloid Leukemia (AML)

The Survivin Suppressant YM155 (Sepantronium Bromide) Has Potent Pre-Clinical Activity Against Pediatric Acute Myeloid Leukemia

The Ratio of Alternate BIRC5 (Survivin) Splice Variants Correlates with Refractory Disease and Poor Outcome in Children with Acute Myeloid Leukemia: A Report From the Children's Oncology Group,

Resistance to Selective FLT3 Inhibitors, Driven by FLT3 Ligand and FLT3 Point Mutations, Can Be Overcome with the Dual FLT3-Aurora Kinase Inhibitor CCT241736,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only